Home › Research › Treatments
Comparison of safety of lecanemab and donanemab: a real-world disproportionality analysis using the FDA adverse event reporting system
Feng X, Bi S, Shi C, Chang Q, Zhang J, Zhuang Y.. Frontiers in pharmacology, 2026-06-22
Topic: Risk, prevention and care in population studies
Plain-language summary
Although both agents have demonstrated therapeutic potential, their post-marketing adverse event reporting profiles remain insufficiently characterized and compared in spontaneous reporting systems. This study aimed to systematically compare adverse event signals associated with these two drugs using the FDA Adverse Event Reporting System database, with sex-stratified and sensitivity analyses performed to support the main findings. Results A total of 3,640 AE reports were identified, including 2,602 for lecanemab and 1,038 for donanemab. Conclusion Using four signal detection algorithms, this study compared real-world adverse event reporting profiles associated with lecanemab and donanemab. These findings provide pharmacovigilance evidence for targeted safety monitoring and hypothesis generation, but should not be interpreted as causal associations or true incidence estimates.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Feng, X., Bi, S., Shi, C., Chang, Q., Zhang, J., & Zhuang, Y. (2026). Comparison of safety of lecanemab and donanemab: a real-world disproportionality analysis using the FDA adverse event reporting system. Frontiers in pharmacology. https://doi.org/10.3389/fphar.2026.1868789
Vancouver
Feng X, Bi S, Shi C, Chang Q, Zhang J, Zhuang Y. Comparison of safety of lecanemab and donanemab: a real-world disproportionality analysis using the FDA adverse event reporting system. Frontiers in pharmacology. 2026. doi:10.3389/fphar.2026.1868789. PMID: 42440686.
BibTeX
@article{feng2026-42440686,
author = {Feng, X. and Bi, S. and Shi, C. and Chang, Q. and Zhang, J. and Zhuang, Y.},
title = {{Comparison of safety of lecanemab and donanemab: a real-world disproportionality analysis using the FDA adverse event reporting system}},
journal = {Frontiers in pharmacology},
year = {2026},
doi = {10.3389/fphar.2026.1868789},
pmid = {42440686},
url = {https://doi.org/10.3389/fphar.2026.1868789}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Although both agents have demonstrated therapeutic potential, their post-marketing adverse event reporting profiles remain insufficiently characterized and compared in spontaneous reporting systems.
- This study aimed to systematically compare adverse event signals associated with these two drugs using the FDA Adverse Event Reporting System database, with sex-stratified and sensitivity analyses performed to support the main findings.
- Results A total of 3,640 AE reports were identified, including 2,602 for lecanemab and 1,038 for donanemab.
- Conclusion Using four signal detection algorithms, this study compared real-world adverse event reporting profiles associated with lecanemab and donanemab.
- These findings provide pharmacovigilance evidence for targeted safety monitoring and hypothesis generation, but should not be interpreted as causal associations or true incidence estimates.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants3,640
- Evidence strengthLow
How this study scored 57/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 33 of the 58 points we could judge it on, which is 57 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Frontiers in pharmacology) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 3 / 4 | 3,640 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42440686) |
| Free to read | 2 / 2 | Free to read |
| Points | 33 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 33 of the 58 points we could judge it on is 57 out of 100. |
| Total | 57 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “disproportionality”
2 studies in the library carry the topic tag “disproportionality”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 2 tagged studies.